Kaempferol Absorption and Pharmacokinetics Evaluation

Conditions

• Healthy Volunteers
• Longevity
• Mitochondria Health
• No Disease
• Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Accepted

Interventions

• Kaempferol — DIETARY_SUPPLEMENT
  Kaempferol (KMP) is administered orally as encapsulated doses once daily for 8 consecutive days in healthy adult participants under controlled dietary conditions. This intervention is designed specifically for intensive pharmacokinetic characterization and biological absorption assessment, incorporating high-frequency serial blood and urine sampling across multiple time points. In contrast to typical dietary supplement studies, this intervention integrates comprehensive multi-omics profiling (including transcriptomics, miRNA-seq, metabolomics, lipidomics, proteomics, and genomic analyses) to evaluate mechanistic and functional biological responses to Kaempferol exposure. Safety and tolerability are monitored throughout the intervention period.

Study Details

This study is a multi-site clinical trial designed to evaluate how the body absorbs and processes Kaempferol, a naturally occurring compound found in many plant-based foods. The primary purpose of the study is to measure the pharmacokinetics and biological absorption of Kaempferol in healthy adults. Participants will receive Kaempferol and undergo scheduled blood and urine collections over a short study period. These samples will be used to measure Kaempferol levels in the body and to assess safety and tolerability. In addition, selected biological samples will be analyzed to explore molecular changes associated with Kaempferol exposure using advanced laboratory methods. The study will be conducted at multiple research centers in the United States using a standardized protocol to ensure consistency across sites. The information collected will help improve understanding of how Kaempferol is absorbed and metabolized in humans and will support future research and regulatory evaluation.

Key Dates

Start date

Dec 9, 2025

Status verified

Mar 2026

Primary completion

Dec 9, 2026

Completion

Dec 22, 2027

Study Design

Enrollment

120 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: Kaempferol Intervention Arm
  Participants in this single-arm intervention receive oral Kaempferol (KMP) administered as capsules once daily for 8 days as part of a controlled dietary regimen. All participants undergo standardized pharmacokinetic blood and urine sampling at predefined time points, along with safety monitoring and comprehensive multi-omics analyses to assess absorption, metabolism, tolerability, and biological responses to Kaempferol.

Primary Outcome Measure

Maximum plasma concentration (Cmax) of Kaempferol [ Time Frame: From dosing on Day 1 through 24 hours after the final dose (Day 8) ]

Central Contacts

• Afshin Beheshti, PhD
  6173082540
  [email protected]
• Arabella Johnson
  +13155659660
  [email protected]

Locations (3)

Find similar trials in New York, NY

Related Studies

• Chronic Transcutaneous Stimulation to Promote Motor Function and Recovery in Individuals With Paralysis or Paresis
  EARLY_PHASE1 · Recruiting · Northwell Health · Manhasset, New York
• A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers
  PHASE1 · Enrolling By Invitation · Memorial Sloan Kettering Cancer Center · New York, New York
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
  PHASE1 · Recruiting · Radiopharm Theranostics, Ltd · Princeton, New Jersey
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  PHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama